Beyond LDL Cholesterol, a New Role for PCSK9

被引：50
|
作者：
Akram, Omar N. [1 ,2 ]
Bernier, Adeline [1 ,3 ]
Petrides, Francine [1 ]
Wong, Gida [1 ,4 ]
Lambert, Gilles [1 ,5 ]
机构：
[1] Heart Res Inst, Lipid Res Grp, Sydney, NSW, Australia
[2] Univ Sydney, Sch Med, Sydney, NSW 2006, Australia
[3] Ecole Normale Super, F-75231 Paris, France
[4] Queen Elizabeth Hosp, Hong Kong, Hong Kong, Peoples R China
[5] Univ Nantes, Fac Med, Nantes, France
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2010年 / 30卷 / 07期
关键词：
atherosclerosis; lipoproteins; metabolism; DENSITY-LIPOPROTEIN-RECEPTOR; DOMINANT HYPERCHOLESTEROLEMIA; PLASMA-CHOLESTEROL; NONHUMAN-PRIMATES; MICE; PROPROTEIN-CONVERTASE-SUBTILISIN-KEXIN-TYPE-9;
D O I：
10.1161/ATVBAHA.110.209007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1279 / 1281
页数：3
相关论文
共 50 条
  • [41] New Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide
    Landmesser, Ulf
    Makhmudova, Umidakhon
    CIRCULATION, 2023, 148 (02) : 159 - 161
  • [42] Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors
    Rita Del Pinto
    Davide Grassi
    Giuliana Properzi
    Giovambattista Desideri
    Claudio Ferri
    High Blood Pressure & Cardiovascular Prevention, 2019, 26 : 199 - 207
  • [43] Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors
    Del Pinto, Rita
    Grassi, Davide
    Properzi, Giuliana
    Desideri, Giovambattista
    Ferri, Claudio
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2019, 26 (03) : 199 - 207
  • [44] Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
    Bandyopadhyay, Dhrubajyoti
    Ashish, Kumar
    Hajra, Adrija
    Qureshi, Arshna
    Ghosh, Raktim K.
    JOURNAL OF LIPIDS, 2018, 2018
  • [45] PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab
    Dahagam, Chanukya
    Goud, Aditya
    Abdelqader, Abdelhai
    Hendrani, Aditya
    Feinstein, Matthew J.
    Qamar, Arman
    Joshi, Parag H.
    Swiger, Kristopher J.
    Byrne, Kathleen
    Quispe, Renato
    Jones, Steven R.
    Blumenthal, Roger S.
    Martin, Seth S.
    FUTURE CARDIOLOGY, 2016, 12 (02) : 149 - 157
  • [46] PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab
    Dahagam, Chanukya
    Goud, Aditya
    Abdelqader, Abdelhai
    Hendrani, Aditya
    Feinstein, Matthew J.
    Qamar, Arman
    Joshi, Parag H.
    Swiger, Kristopher J.
    Byrne, Kathleen
    Quispe, Renato
    Jones, Steven R.
    Blumenthal, Roger S.
    Martin, Seth S.
    FUTURE CARDIOLOGY, 2016, 12 (02) : 139 - 148
  • [47] Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease
    Folsom, Aaron R.
    Peacock, James M.
    Boerwinkle, Eric
    ATHEROSCLEROSIS, 2009, 202 (01) : 211 - 215
  • [48] Back to Basics: PCSK9 as a New Target for the LDL Receptor
    Corral, Pablo
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2014, 102 (01) : E5 - E8
  • [49] PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
    Luquero, Aureli
    Badimon, Lina
    Borrell-Pages, Maria
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [50] LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy
    Hamasaki, Masato
    Sakane, Naoki
    Hara, Kazuo
    Kotani, Kazuhiko
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (11)
12345